While survivial in general in Systemic Lupus Erythematosus (SLE) has improved a marked increased incidence of cardiovascular disease (CVD) has become more apparent [1, 2] . The rate of death from CVD was estimated to be three times higher in SLE patients than in the general population. Mortality due to both coronary heart disease and stroke was increased, and vascular mortality rates seemed to have remained constant since 1964 [3] .
Several traditional CVD risk factors are prevalent in SLE patients, but they do not fully account for the high incidence of CVD [4] . Additionally SLE related factors e.g. antiphospholipid antibodies (aPL) and pro-inflammatory biomarkers seem to be important [5] [6] [7] . A genetic deficiency of mannose-binding lectin [8, 9] and a polymorphic GT repeat in the CRP gene (CRP GT 20 ) [10] were previously reported to be associated with arterial events in SLE. However, no study has evaluated the association between CVD in SLE and the common susceptibility genes for this disease, recently identified in whole genome association studies [11, 12] .
The signal transducer and activator of transcription factor 4 (STAT4) has reliably been demonstrated to be one of the strongest genetic susceptibility factors for SLE. The STAT4 risk alleles is associated with a more severe SLE phenotype characterized by younger age at disease onset, higher frequency of nephritis and presence of anti-double stranded DNA antibodies [11] [12] [13] [14] [15] [16] [17] .
STAT4 transmits signals from the receptors for type I IFN, IL-12 and IL-23 and it appears to be a critical mediator for several pro-inflammatory cyto-and chemokines including interferon-α (IFN-α) [18] . Increased production of IFN-α, present in a majority of SLE patients [19] may contribute to vascular vulnerability in SLE through amplifying inflammatory activity in atherosclerotic plaques and may also impair endothelial progenitor cell differentiation [20] .
We have previously investigated a set of 53 common single nucleotide polymorphisms (SNPs) in the STAT4 gene. Ten of these SNPs were associated with SLE [17] . The strongest signal of association was observed for two perfectly linked STAT4 SNPs, rs10181656 and rs7582694 (r 2 = 1.0), which are in perfect linkage disequilibrium with the SNP rs7574865, also shown to be associated with SLE [21] . Either one of these SNPs accounted for the entire observed association signal in our study [17] . We therefore used the SNP rs10181656(G) as a representative of the STAT4 SLE risk allele and investigated its association with vascular manifestations and presence of pro-thrombotic aPL in two independent SLE groups.
Methods
Study population: Two patients groups with SLE were included. The first group is from the rheumatology clinics at Karolinska and Uppsala University hospitals (Mid-Sweden, n=443). The second group is from Lund University hospital (Southern-Sweden, n=154). All patients attending the respective hospitals were invited to participate. If patients were related only the first case in each family was included; thus the study population included unrelated patients. A rheumatologist examined all patients and their medical records. All patients fulfilled at least four of the American College of Rheumatology (ACR) classification criteria for SLE [22] . Organ damage was estimated using the Systemic Lupus International Collaborating Clinics (SLICC)/ACR damage index [23] . The regional ethical boards approved the study. All study participants gave informed consent to participate. We explored risk allele frequencies in subgroups of SLE patients as defined by the occurrence of previous vascular events or a positive test for aPL of different specificities. Matched controls were genotyped to give a comparison to the local genetic background. Control samples from Mid-Sweden were from healthy blood donors (n=153) or from population-based individuals (n=309) matched for age, sex, ethnicity and region of living. Control samples from Southern-Sweden (n=194) were from healthy blood donors matched for ethnicity and region of living. Standard procedures were used to extract DNA from blood samples.
Outcomes:
Vascular events were objectively verified (see supplementary material for detailed definitions): 1) Ischemic heart disease (IHD); Myocardial infarction (MI), and/or angina pectoris 2) Ischemic cerebrovascular disease (ICVD); Ischemic stroke and/or transitory ischemic attacks (TIA). 3) Ischemic peripheral vascular disease (IPVD); Intermittent claudication and/or peripheral arterial thrombosis or embolus. With "any arterial event" (AAE) we refer to the occurrence of one or more of 1-3. 4) Venous thromboembolism (VTE); deep vein thrombosis and/or pulmonary embolism. Antibodies and Lupus anticoagulant: Antibodies against (a) cardiolipin (CL, IgG and IgM), beta2-glycoprotein-1 (βGP-1, IgG) and prothrombin (PT, IgG) were successfully analyzed by ELISA (Orgentec, Mainz, Germany) in > 99% of frozen serum samples. The cut off levels corresponded to the 99th percentile of healthy blood donors. Lupus anticoagulant (LAC) was determined with a modified Dilute Russel Viper Venom method, (Biopool, Umeå, Sweden) using Bioclot lupus anticoagulant. Genotyping: The SNP rs10181656 in intron 3 of the STAT4 gene was genotyped using the Golden Gate assay (Illumina Inc., San Diego, CA, USA) [24] in 497 SLE cases and 536 controls from Mid and Southern Sweden as previously described and presented [17] . The genotype call rate was 97.0% and the reproducibility 100% as determined by duplicate genotyping of 17 samples. An additional, partly overlapping, set of 417 subjects was genotyped using the SNPstream system (Beckman-Coulter Inc., Fullerton, CA, USA). This method uses PCR amplification followed by single-base primer extension with fluorescent ddNTPs [25] . The sequence of the forward PCR primer was 5'TGGGAAAATAGTTTTCAAAGTCTAA'3 and that of the reverse primer was 5'AAGATGGTGACAAGCCAGG'3, and the sequence of the detection primer was 5'ACTAGCTGGAATCCAACTCTTCTCA'3. For this assay the genotype call rate was 97.6% and the reproducibility 100% as determined by duplicate genotyping of 191 samples. For the overlapping set of 156 individuals successfully genotyped by both assays the concordance between platforms was 100%. After exclusion of 24 non-Swedish individuals, genotypes were available for 424 unrelated patients and 457 controls from Mid-Sweden, and from 154 unrelated patients and 194 controls from Southern Sweden, resulting in a total of 578 patients and 651 controls available for analysis. The genotypes of the SNP rs10181656 in controls and cases from both cohorts conformed to Hardy-Weinberg equilibrium (p > 0.05). Statistical analysis: Clinical patient characteristics and allele frequencies between groups were compared with chi-squared tests. Continuous variables were analyzed using MannWhitney U-test or Kruskal Wallis test. Fisher's exact test was used to test for HardyWeinberg equilibrium of genotypes. Odds ratios (OR) and 95% confidence intervals (CI) were calculated from 2x2 contingency tables and Mantel-Haenszel estimates were used for summary measures. Univariate and multivariable-adjusted logistic regression analyses estimated the impact of risk factors on ICVD and IHD events. Gender, cohort, 1 or 2 vs 0 STAT4 risk factors and all covariates with p≤0.05 were entered into an all inclusive multivariable-adjusted models. Data processing was performed using "JMP" software (SAS Institute Inc, Carey, North Carolina). For power analysis see supplementary material.
Results

Patients:
Characteristics of the SLE patients are given in Table 1 . Among the patients, 61 individuals had experienced an ICVD event of which 10 suffered from at least one TIA but no stroke. 66 patients had a history of IHD; 15 presented with isolated symptoms of angina pectoris while the remainder had been diagnosed with MI. Figures are number (%) or mean ± standard deviation if not otherwise stated, SLE criteria as defined [22] , SLICC/ACR damage index [23] , any arterial event = ischemic cerebrovascular disease and/or ischemic heart disease and/or ischemic peripheral vascular disease, + = positive test for, a = anti, CL= cardiolipin, Ig = immunoglobulin, β2GP-1= beta2glycoprotein-1, PT = prothrombin, ≥2aPL = two or more positive tests among aCL IgG, aCL IgM, aβ2GP-1 or aPT, *tested in 289 patients from MidSweden Associations between STAT4 risk allele and vascular events: We observed a higher frequency of the STAT4 SNP rs10181656(G) in SLE patients with previous arterial events, than in SLE patients without arterial events. There was no association between the STAT4 risk allele and VTE. The association with previous arterial events was mainly attributable to the group of patients with ICVD manifestations, while manifestations of IHD or PIVD were not associated with the risk allele. When excluding the 10 patients with TIA the association remained of similar magnitude. Results were consistent in the two patient groups and when combined, the associations were strengthened. Comparison of the risk allele frequency between patients and controls demonstrated that patients with arterial events contributed substantially more to the association signal with SLE as compared to patients free of arterial events (Table 2) .
A dose dependent relationship between previous manifestations of ICVD and the number of risk alleles was apparent ( Figure 1a ). The combined OR for ICVD in SLE patients homozygous for the rs10181656(G) allele in comparison with other SLE patients was 3.2 (95%CI: 1,7-6,2, p=0.0002). 77% of SLE patients with previous ICVD were carriers of one or two copies of the risk allele.
Associations between the STAT4 risk allele and antiphospholipid antibodies: In the MidSweden cohort STAT4 was associated with the simultaneous occurrence of two or more positive aPL (≥2aPL) and with a positive LAC test. In the Southern-Sweden cohort a weak association with a positive test for aCL, IgM and aPT was detected. Analysis of the combined patient groups yielded significant ORs for an association between the STAT4 risk allele and occurrence of ≥ 2 aPL and a suggestive but non significant association was observed for aCL IgM and aPT (Table 3 ). There was a dose dependent relationship in the combined patient groups between the number of STAT4 risk alleles and the percentage of patients with ≥2 aPL (Figure 1b) . The number of risk alleles was also associated with the level of LAC positivity (p=0.002), but not with the level of the individual aPLs (data not shown).
Risk factors for vascular events:
Adjustment for available known risk factors did not attenuate the association between the STAT4 risk allele and vascular events. Any STAT4 risk alleles emerged as a strong risk factor for ICVD in SLE patients (OR=3.3, 95%CI: 1.7-6.7). A positive test for aCL IgG also remained as an independent risk factor for ICVD (OR=2.6, 95%CI:1.3-4.9). STAT4 genotype did not significantly contribute to the occurrence of IHD or VTE. aPL were associated with ICVD and VTE but there was no convincing association between aPL and IHD (Table 4) . ard.bmj.com Discussion Our major finding is that the number of STAT4 risk alleles (SNP rs10181656(G)) are associated with an increased risk of ICVD in SLE in a dose-dependent manner. The risk allele was furthermore associated with occurrence of pro-thrombotic aPL indicating a possible mechanistic connection between genotype and ICVD phenotype. Our observations imply that STAT4 genotype is a previously unknown major risk factor for ICVD, a feared complication, which affected 10% of the patients in the present study.
Combined groups
The STAT4 risk variants were linked to occurrence of antibodies against double stranded DNA in previous studies [17, 21] and we noted an association with the immunological ACR criteria [22] (p=0.02, supplementary table 1) and more severe disease, as measured by SLICC/ACRdamage index (p=0.03) [23] . Pro-thrombotic aPLs are autoantibodies, which target membrane phospholipids and associated protein co-factors. APLs are established risk factors for both venous and arterial events [26] . They occur in the antiphospholipid syndrome (APS) and are detectable in 25-40% of SLE patients [27] . Familial aggregation of APS has been reported and genetic analyses suggest a dominant pattern of inheritance, but the genes involved have not yet been identified [28] . We investigated four aPL specificities and performed a LAC test on 289 patients from Karolinska University Hospital. LAC is the most relevant test for aPLs associated with thromboembolic manifestations regardless of site and type of thrombosis [26, 29] . To have antibodies to more than one aPL specificity confers a higher risk of thromboembolic complications as well [26] . A clear association between the STAT4 risk allele and the occurrence of two or more aPLs, a positive LAC and a higher level of LAC was present. These observations indicate that the STAT4 risk variant promotes the production of clinically significant aPLs. Two recent studies corroborate our findings demonstrating an association between the STAT4 risk allele and APS [30, 31] . Our results are also in line with the prominent role of STAT4 in B cell activation and autoantibody production observed in lupus prone mice [32, 33] . Thus, one mechanism by which STAT4 could increase the risk for ICVD is by an increased production of several prothrombotic aPL.
Both ICVD and IHD were comparably frequent in our study, however only ICVD was associated with the STAT4 risk allele. ICVD is often a thomboembolic complication while IHD is believed to principally be a consequence of premature atherosclerosis [34] . This study demonstrates that traditional risk factors such as smoking, diabetes and gender have a stronger association with IHD than with ICVD in SLE. Additional risk factors such as hyperlipidemia and markers of systemic inflammation, not investigated in the present study, clearly also contribute to both IHD and ICVD [5-7, 35, 36] . Apart from this, this study demonstrates that risk profiles for IHD and ICVD may differ, with respect to risk factors other than STAT4 genotype, suggesting differences in the etiopathogenesis of these two types of arterial manifestations in SLE.
The STAT4 risk allele was not associated with VTE despite the association between VTE and aPLs. Many established risk factors for VTE are hereditary and differ from those of arterial thrombosis [37] . In longitudinal studies, recurring thrombosis in APS patients are often of the same type, i.e. arterial or venous, as the initial presentation [38] . Emerging data also suggest that vessel-specific inflammation [39] may be pivotal for development of arterial, but not venous thrombosis [37] . Another study demonstrated that serum levels of endothelium-derived endothelin-1, a marker of endothelial activation, were able to discriminate APS patients with stroke from APS patients with venous thrombosis [40] . Thus, several factors, possibly including STAT4 genotype, may contribute to a personal predisposition for either arterial or venous manifestations in patients with aPL.
STAT4 mediates IL-12 dependent activation of natural killer (NK) cells and polarization of naïve CD4+ T cells to IFN-γ producing T-helper (Th)1 cells [18] . Both Th-1 cells and IFN-γ, which activates macrophages, are prevalent in human carotid arteries and preferentially tend to localize in the rupture prone shoulder regions of atherosclerotic plaques [34] . IFN-α producing PDCs are also present in atherosclerotic plaques from carotid lesions where they can act as inflammatory amplifiers [41] . Recently, it was shown that a STAT4 risk allele, perfectly linked to rs10181656, confers augmented sensitivity to IFN-α in SLE patient [42] . Consequently, STAT4 activity could promote the risk of plaque rupture and thrombosis by increasing the local inflammatory response. Though consecutively gathered these SLE patients are not random samples. Differences in collection procedures may, as previously described[1, 43, 44] , explain the observed discrepancies between the two SLE groups in this study. The Mid-Sweden group is collected at University hospitals, which are tertiary academic centers, where patients were younger at disease onset and at follow up. They also had a higher risk allele frequency. The Southern-Sweden group is collected in Lund where a longitudinal SLE cohort is well established since the mid 80's. This epidemiological cohort aims to investigate all cases of lupus in a defined catchment area (Lund-Orup). However, for the present study, consecutively included SLE patients outside the catchment area were also enrolled. We find our results biologically plausible and regarding ICVD they were replicated in two patient groups. Nevertheless, they should be interpreted with some caution since we did not correct for multiple testing. Despite this and differences in collection procedures, the associations between the STAT4 risk allele and ICVD were not only replicated but also of similar magnitude and direction in both SLE groups, supporting the robustness of our results. Further studies are clearly needed to understand why STAT4 risk alleles are associated with ICVD but not with other types vascular events.
In conclusion our data demonstrate that the STAT4 genotype is associated with SLE-related ICVD and with pro-thrombotic aPLs, but not with IHD or VTE. ICVD is an important manifestation of CVD, a major cause of premature mortality among SLE patients. We can here for the first time identify a genetic contribution, which seems to predispose some SLE patients to ICVD. Whether STAT4 genotype also contributes to clinical presentation with ICVD in primary APS, other chronic inflammatory conditions, or in the general population remains to be determined; However, STAT4 risk alleles have recently been associated with other autoimmune diseases among them rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease [16, [45] [46] [47] 
